Introduction
Adenomyosis is a chronic disease of the female
reproductive system that affects up to 60% of women
of reproductive age worldwide [1]. Adenomyosis is
characterised by benign invasion of the endometrium
into the myometrium [2]. Disruption of myometrium
leads to pathology that affects female reproductive
health and includes multiple clinical manifestations
including excessive uterine bleeding, dysmenorrhea,
chronic pelvic pain, and reduced fertility [3, 4]. Despite
well-defined clinical characteristics of adenomyosis,
molecular and cellular mechanisms that underlie the
disease origin and progression remain poorly under -
stood. Determining the molecular basis of the develop-
ment of adenomyosis will help design better diagnostic
tools and treatment regimens for women.
A number of factors have been proposed to con-
tribute to the development of adenomyosis including
angiogenic abnormalities [5], hormonal imbalance
[6], and genetic factors [7]. More recently, a number of
studies have revealed the importance of the immuno-
logical and pathogenic components in a related endo-
metrial condition endometriosis [8, 9]. A local immune
dysregulation as well as changes in the microbiome in
the genital tract have been shown to play a role in the
disease development [10]. Infectious agents including
bacteria, viruses and fungi can serve as a trigger to ini-
tiate a dysbiosis in the genital tract leading to chronic
inflammation and immune dysregulation [11, 12]. The
inability of the immune system to resolve inflammation
and clear the infection agents results in tissue damage
and pathogenesis. Understanding the immunological
networks of endometrial-myometrial pathology will
be invaluable in defining the biological markers of the
disease.
There are multiple lines of defence against the
harmful factors that lead to the changes in the female
reproductive flora and contribute to the disease pro -
gression. The first line of defence includes cytokines
and antimicrobial peptides (AMPs) released by immune
The analysis of cervicovaginal microbiota and immune
mediators in patients with adenomyosis
Mykola Shcherbina, Liliya Potapova, Oksana Lipko, lrina Shcherbina, Anastasiia Chekhunova, Olga Mertsalova
KHARKIV NATIONAL MEDICAL UNIVERSITY , KHARKIV , UKRAINE
Abstract
Aim: To determine and characterise changes associated with microbial, inflammatory and immune factors in patients with adenomyosis.
Materials and methods
115 female patients were enrolled in the study, including 85 patients with adenomyosis and 30 healthy individuals. Vaginal
cleanliness was assessed by collecting vaginal samples and plating on solid bacterial agar. Urogenital infections were determined by the PCR analysis of the
cervicovaginal samples. The immunological characterisation was performed using enzyme immunoassay to analyse cervicovaginal lavage for β-defensin-2
and a defined set of cytokines. Antibody titers were quantified in patients’ serum using nephelometry.
Results
Patients with adenomyosis displayed disrupted cervicovaginal microflora that was characterised by elevated levels of pro-inflammatory cytokines
and antimicrobial peptide β-defensin-2. Serum analysis of patients with adenomyosis revealed higher concentration of IgG, IgM and IgA antibodies compared
to healthy control groups.
Conclusions
Analysis of inflammatory and immunological parameters in patients with adenomyosis revealed distinct features of the pathophysiology of
adenomyosis. Specifically, patients with adenomyosis had disrupted cervicovaginal microflora with higher prevalence of anaerobic species. Furthermore,
patients with adenomyosis had elevated levels of pro-inflammatory cytokines and interleukins in cervicovaginal lavage, and higher levels of IgG, IgM and
IgA antibody serum titres. The analysis presented in the paper represents an important step towards determining precise diagnostic parameters and effective
therapies to treat adenomyosis.
Keywords
antimicrobial peptides, adenomyosis, cervicovaginal microbiome
Wiad Lek. 2026;79(7):1493-1499. doi: 10.36740/WLek/218754 DOI
ORIGINAL ARTICLE CONTENTS
Mykola Shcherbina et al.
1494
cells in response to microbial agent, inflammation
and physical damage [13]. There are approximately
39 antimicrobial peptides in cervicovaginal fluid [14]
with β-defensins family, cathelicidin and SLPIs being
the most dominant AMPs [15]. Multiple reports have
demonstrated the importance of AMPs in the protec -
tion of vaginal microbiome [16, 17]. However, the role
of AMPs in adenomyosis remains poorly understood.
Release of AMPs, such as β-defensins, serves as a che -
moattractant for immune cells. Following AMPs release,
monocytes and dendritic cells migrate to the site of
infection and can phagocytose and present pathogen
associated molecular patters for T cell recognition. Upon
activation, T cells trigger the next line of defence known
as the adaptive immunity that involves activation of B
cells and production of different antibodies including
IgG, IgM and IgA that act at mucosal barriers as well
and tissues and blood [18].
In this work, we defined the components of innate
and adaptive immunity in the cervicovaginal micro -
environment in patients with adenomyosis. We show
that both microflora and immune composition is al-
tered when adenomyosis is present, implicating these
changes in disease progression.
AIM
To determine and characterize changes associated with
microbial, inflammatory and immune factors in patients
with adenomyosis.
Materials and methods
PATIENTS INVOLVED IN THE STUDY
115 female patients aged 18-45 years old, who under-
went treatment at the clinical bases of the Department
of Obstetrics and Gynecology No. 1 of the KhNMU,
took part in the study. The patients were assigned into
groups as follows. The first clinical group (study group)
included 85 (73.9% of the total number of patients
enrolled in the study) patients with adenomyosis. The
second clinical group (control group) consisted of 30
(26.1% of the total number of patients enrolled in the
study) healthy fertile women. All patients underwent a
routine general clinical examination during the course
of the study, in accordance with the current clinical
recommendations of the Ministry of Health of Ukraine.
The examination was carried out after obtaining the
patient’s informed consent for the diagnosis and pro-
cessing of personal data.
Adenomyosis was diagnosed in patients in the
study group based on the diagnostic tools and
histological methods of examination of tissues ob -
tained during hysteroscopy. Patient exclusion criteria
included extragenital pathology, oncology includ -
ing leiomyomas, inflammation of the genitals, HPV
infection. Patients who were exposed to urogenital
viral or bacterial infection in the last 6 months and
who underwent antibiotic therapy were excluded
from the study.
ETHICS STATEMENT
The study was conducted in compliance with the basic
bioethical norms and requirements of the Helsinki Dec-
laration of the General Assembly of the World Medical
Association on Human Rights and Biomedicine (1977),
in accordance with the provisions of the WHO, the In-
ternational Council of Medical Scientific Societies, the
International Code of Medical Ethics (1983) and the
Order of the Ministry of Health of Ukraine No. 690 dated
September 23, 2009. The study protocol was approved
by the Bioethics Commission of the KhNMU.
[World Medical Association Declaration of Helsinki
“Ethical Principles of Medical Research Involving Human
Subjects” . 2008. URL : https://zakon.rada.gov.ua/laws/
show/990_005]
DETECTION OF UROGENITAL INFECTIONS
Vaginal cleanliness was determined by isolating the
Lactobacilli strains from vaginal samples using standard
procedure of culturing bacteria on solid agar and by
performing subsequent PCR sequencing.
To determine the presence of anaerobic bacteria, cer-
vicovaginal lavage (CVL) was analyzed for the presence
of the indicated microbial agents (Table 1). Bacterial
agents were detected by PCR using standard procedure.
IMMUNOLOGICAL CHARACTERISATION
CVL samples were collected and the levels of cytokines
were determined by solid-phase enzyme immunoassay
Method
using Stat Enzyme Immunoassay Analyzer Fax
® 303 Plus (Awareness Technology, Inc. USA ) according
to manufacturer instructions.
ANALYSIS OF ANTIBODIES IN BLOOD
Blood samples were collected during the study and
processed immediately post-collection. Serum was
separated from whole blood samples by centrifugation
at 2,000g for 15 min at 4 oC. Separated serum samples
were analysed for total immunoglobulins IgG, IgM and
IgA using nephelometry.
The analysis of cervicovaginal microbiota and immune mediators in patients with adenomyosis
1495
STATISTICAL ANALYSIS
Statistical analysis was performed using software pack-
age “Statistica 10.0 for Windows” . For each variation
series, we calculated average arithmetic mean (M), av-
erage quadratic deviation (σ), average mistake average
arithmetic (m). To identify significant differences, Mann-
Whitney U test was used. Differences were considered
significant at a level of P < 0.05.
RESUL TS
ANALYSIS OF BACTERIAL COMPOSITIONS
IN THE CERVICOVAGINAL SECRETIONS IN
PATIENTS WITH ADENOMYOSIS
There were 115 female patients involved in the study
and the patients were divided into two groups. Group
1 constituted patients with adenomyosis diagnosis
(study group, 85 patients) and group 2 included healthy
patients (control group, 30 patients). The patients were
31.2 ± 2.7 years old, with no statistical difference in
age between the study or control groups. 30% of the
patients in the study group contained cases of gyne -
cological complications and family history of gynae -
cological conditions compared to 10% in the control
group. Average duration of adenomyosis in patients
in study group was between 3 to 5 years. The clinical
signs of pathology in the study group included pelvic
pain (71% of patients), dysmenorrhea (43% patients)
and infertility (84% patients).
First, we aimed to determine the degree of vaginal
cleanliness among all the patients enrolled in the study.
We used previously reported lactobacilli grading meth-
od [19] to define four degrees of purity of vaginal flora:
Grade I defined as dominant lactobacilli with no other
bacteria present, Grade II defined as having lactobacilli
and other bacteria present, Grade II defined as few or
no lactobacilli with other bacteria present and Grade
IV defined as no lactobacilli and no other bacteria pres-
ent. Vaginal discharge was collected from patients and
bacterial flora was examined using PCR (Table 1). Grade
I vaginal purity was detected in 24 (80.0%) women
of the control group and in 8 (9.4%) patients in the
study group. Grade II-III vaginal purity was identified
in 6 (20.0%) control group patients and in 71 patients
(83.5%) of the study group. Grade IV vaginal purity was
present in 6 (7.1%) of cases in patients of the study
group and was not detected in any of the patients in
Table 1. Cervicovaginal cleanliness in the examined patients
Degree of vaginal cleanliness
Study group (n=85) Control group (n=30)
n % n %
I 8 9.4 24 80
II-III 71 83.5 6 20
IV 6 7.1 - -
% is percentage out of the total number of examined patients per group
n-number of patients
Source: compiled by the authors of this study
Table 2. Concentration of antimicrobial peptide β-defensin-2 and cytokines in the cervicovaginal lavage of the examined patients.
Study group Control group
n=85 n=30
Antimicrobial peptide (AMP) ng /ml
β-defensin-2 30.5±3.5* 46.7±3.8
Cytokines pg /ml
IL-4 20.0±1.8* 15.3±1.5
IL-8 4.94±0.6* 3.8±0.4
IL-10 8.37±0.2* 7.1±0.9
IL-18 14.0±1.5* 10.9±1.3
TNFα 43.2±4.5* 33.4±3.6
VEGF 228.5±25.1* 173.5±16.9
IFNg 9.54±1.1* 7.9±0.2
Mann-Whitney U test was performed. Mean±SEM is shown where SEM is standard error of the mean. *P<0.05 was considered statistically significant
between the control and study groups. n is number of patients per group
Source: compiled by the authors of this study
Mykola Shcherbina et al.
1496
There different types of AMPs in the endometrial fluid
[24] and β-defensins are of the most abundant AMPs
present. As a representative analysis, we, chose to
look at the levels of β-defensin-2 in CVL fluid in the
study and control groups. The levels of b-defensins
were downregulated in patients with adenomyosis
compared to the control group (Table 2). This result
supported the link between adenomyosis and dysreg-
ulated microflora.
CERVICOVAGINAL INFLAMMATORY
CHANGES IN PATIENTS WITH ADENOMYOSIS
We hypothesised that disrupted microbial composition
within the vaginal environment may also be accompa-
nied by immunological changes.
We therefore examined the levels of the key immu-
nological regulators including interleukins (IL-4, IL-8,
IL-10, IL-18), pro-inflammatory mediators (TNFα, IFNγ)
and endothelial growth factor (VEGF) in the CVL in the
study and control groups. In CVL, the concentration
of IL-8, IL-10 and IL-18 was significantly higher in
patients with adenomyosis compared to the control
group (Table 2). Since IL-18 stimulates the formation
of Th1-type cytokines (IFNγ, TNFα), its increase at the
local level may be aimed at limiting inflammatory
processes in the reproductive tract. In addition, by
secreting Th1-type mediators, IL-18 may contribute to
the development of a T-cell immune response. In line
with these observations, higher levels of TNFα were
detected in patients with adenomyosis compared to the
study group (Table 2). IL-4 and IL-10, that are associated
with anti-inflammatory responses, were elevated in
patients with adenomyosis. The concentration of VEGF
was significantly higher in the study group compared
to healthy volunteers indicating a possible disruption
in the normal angiogenesis that may result in vascular
growth and proliferation of ectopic endometrium.
Next, we examined the levels of three subclasses of
antibodies IgG, IgA and IgM in the serum of patients of
adenomyosis or healthy women. All three subclasses of
antibodies were elevated in patients with adenomyosis
the control group. Together, these data indicated that
vaginal purity is negatively affected in patients with
adenomyosis.
Decrease in vaginal purity suggested that microbial
changes may be present in the vaginal environment.
Previous work suggested that there is an association
between anaerobic microbes and inflammation of en-
dometrium [20, 21] which prompted us to ask whether
anaerobic bacteria may play a role in adenomyosis. To
address this question, we examined the anaerobic mi-
crobial composition of the cervicovaginal flora in the
study and control groups. Samples of cervicovaginal
lavage were collected and microbial composition was
determined by PCR for an indicated set of microbial
agents (Fig. 1). Anaerobic microbial agents constitut -
ed seven microorganisms that have previously been
reported in vaginal microflora [22, 23]. Comparison
between the control and study groups revealed that
patients with adenomyosis were characterized by the
presence of a number of anaerobic microorganisms
with the Streptococcus spp. Staphylococcus spp. and
Eubacterium spp. being second and third most abun-
dant anaerobe present respectively. A single case of
Candida spp., and another case of Mycoplasma hominis
were identified in the study group, suggesting that the
presence of these microorganisms is rare yet detect -
able. Unlike the study group, the vaginal microflora
of healthy patients had no presence of any of the an-
aerobic microorganisms, consistent with the control
group exhibiting Grade I degree with vaginal purity
(Table 1). Together, these results suggested a possible
link between the adenomyosis and the presence of
anaerobic species in likely disrupted cervicovaginal
microbiota.
Disruption in microflora in the vaginal environment
in patients with adenomyosis lead us to examine the
local immunological composition. AMPs produced
by commensal microbiota are known to be the key
mediators of defence against microbial pathogens
in female reproductive tract [12]. AMPs are known to
fluctuate in response to hormonal changes as well as
in certain disease of female reproductive tract [13].
Table 3. Concentration of antibodies in the serum of the examined patients.
Study group Control group
n=85 n=30
IgM (g/l) 1.85 ±0.26* 1.02±0.09
IgG (g/l) 16.6 ±2.5* 12.3 ±1.6
IgA (g/l) 2.33 ±0.34* 1.10 ±0.08
Mann-Whitney U test was performed, Mean±SEM is shown where SEM is standard error of the mean. *P<0.05 was considered statistically significant
between the control and study groups. n is number of patients per group
Source: compiled by the authors of this study
The analysis of cervicovaginal microbiota and immune mediators in patients with adenomyosis
1497
of adenomyosis present themselves with defined
patterns of cervicovaginal microbial composition and
expand our analysis to other AMPs in adenomyosis.
The striking difference in pro-inflammatory cytokine
profile between the patients with adenomyosis sug-
gests that immune cell composition at the endometrial
site differs between the adenomyosis patients and
the healthy women. It would be interesting to define
immune subsets in the cervicovaginal microenviron-
ment in patients with adenomyosis to pinpoint the
dominant immune cell populations that trigger the
release of the proinflammatory cytokines identified
in the present study. Interestingly, the levels of two
anti-inflammatory cytokines IL-4 and IL-10 were sim-
ilarly elevated in patients with adenomyosis (Table
2), indicating that even these elevated levels of an-
ti-inflammatory cytokines are insufficient to suppress
inflammation at the lesion site. Future work will focus
on expanding the analysis of cytokine profiles to wider
clinical groups to determine whether the cytokines
can be used as prognosis markers for the development
of adenomyosis [26].
Identifying the association between the elevated an-
tibody levels and the presence of adenomyosis (Table
3) raises an interesting possibility that adenomyosis
may have the autoimmune component its pathophys-
iology, similar to other endometriosis lesions [27]. The
elevated levels of the antibodies in the serum of ade -
nomyosis patients suggests that adaptive immunity
mediated by T and B cells is activated in these patients.
compared to the control group, with IgG levels being
the most dominant class (Table 3). Collectively these
Results
indicated that the inflammatory microenviron-
ment, defined by elevated levels of pro-inflammatory
mediators and increased inflammation-associated
immunoglobulins, may be a characteristic of adeno -
myosis lesions.
Discussion
The results of the study show that adenomyosis may
be accompanied by changes in the cervicovaginal mi-
crobiome, a drop in b-defensin-2 and changes in the
local immunological profile.
Epithelial cells of female reproductive tract are
colonized by commensal bacteria that secrete AMPs
among others, thereby providing protection against
harmful pathogens. Our results showed that patients
with adenomyosis displayed disruption in cervicovag-
inal microbiome that was manifested by the presence
of anaerobic microorganisms (Fig. 1, Table 1). Consis-
tent with this observations, other reports indicated
that endometriosis-related lesions have distinct micro-
bial compositions [11] and different stages of endome-
triosis are characterised by specific microbial patters
[25]. In our study, we did not look at individual stages
of adenomyosis. Furthermore, we only looked at the
levels of β-defensin-2, one of many AMPs secreted by
commensal bacteria in female genital tract. In future,
we would like to determine whether certain stages
Fig. 1. The presence of anaerobic microbial species in cervicovaginal lavage of patients with and without adenomyosis
The number of patients is presented as a percentage per either study (black) or control (grey) groups. Black bars depict patients in the study group
(with adenomyosis, total n=84). No anaerobic bacteria were identified in the control group of patients (n=30) “X” indicates that no patients were
identified with a given microbial species.
Authors’ own work
Fig. 1. The presence of anaerobic microbial species in cervicovaginal lavage of patients with and
without adenomyosis
*The number of patients is presented as a percentage per either study (black) or control (grey)
groups. Black bars depict patients in the study group (with adenomyosis, total n=84). No anaerobic
bacteria were identified in the control group of patients (n=30) “X” indicates that no patients were
identified with a given microbial species.
Picture taken by the authors
Mykola Shcherbina et al.
1498
Conclusions
The pathophysiology of adenomyosis remains understud-
ied largely due to the complexity of the diagnosis and
limited understanding of the etiology of the condition.
The study presented here revealed several important
aspects of the inflammation and immune dysregulation
that accompany adenomyosis lesions. The results showed
that patients with adenomyosis exhibit disrupted micro-
bial composition within the cervicovaginal environment
characterised by high prevalence of anaerobic species.
Cervicovaginal lavage collected from patients with adeno-
myosis was characterized by elevated levels of interleukins
(IL-4, IL-8, IL-10, IL-18), pro-inflammatory mediators (TNFα,
IFNy) and endothelial growth factor (VEGF). Furthermore,
the serum concentrations of IgG, IgM and IgA antibodies
were elevated in patients with adenomyosis compared to
healthy individuals. Our study provides an important foun-
dation to further dissect the immunological composition of
adenomyosis and ultimately help design better diagnostic
and therapeutic tools to treat this debilitating condition.
Follow up studies are necessary to determine whether
these antibodies are acting at the site of adenomyotic
lesion, thereby exacerbating the disease further. An-
other outstanding question remains - what are the
antigens that are recognised by these antibodies in pa-
tients with adenomyosis? Provided the elevated levels
of antibodies in patients with adenomyosis recognize
self-antigens at the adenomyosis lesion, it would be
interesting to investigate whether the mechanism
of immunosuppression might be effective at certain
stages of adenomyosis development.
Adenomyosis remains to be a topical global problem
affecting health of millions of women worldwide and
the current treatment does not address prevention or
pathophysiological aspects of the disease. The study
presented here will contribute to a better under -
standing of the molecular mechanisms that govern
adenomyosis at the cellular level and help advance
the development of much needed diagnostic and
prevention strategies.
References
1. Bourdon M, et al. Adenomyosis: An update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021;50(10):102228.
doi:10.1016/j.jogoh.2021.102228. DOI
2. Bird CC, McElin TW, Manalo-Estrella P . The elusive adenomyosis of the uterus--revisited. Am J Obstet Gynecol. 1972;112(5):583-593.
doi:10.1016/0002-9378(72)90781-8. DOI
3. Taylor MA, Croudace TJ, Muir FE, McBride M. Women’s experiences of living with adenomyosis and perceptions of the diagnostic journey:
a scoping review. BMJ Open. 2025;15(1):e087122. doi:10.1136/bmjopen-2024-087122. DOI
4. eBioMedicine. Adenomyosis: an underacknowledged cause of abnormal uterine bleeding and pelvic pain. eBioMedicine. 2025;113:105656.
doi:10.1016/j.ebiom.2025.105656. DOI
5. Harmsen MJ et al. Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.
Hum Reprod Update. 2019;25(5):647-671. doi:10.1093/humupd/dmz024. DOI
6. García-Solares J, Donnez J, Donnez O, Dolmans MM. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril.
2018;109(3):371-379. doi:10.1016/j.fertnstert.2017.12.030. DOI
7. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update.
2021;27(6):1086-1097. doi:10.1093/humupd/dmab017. DOI
8. Greene AD, Lang SA, Kendziorski JA et al. Endometriosis: where are we and where are we going? Reproduction. 2016;152(3):R63-R78.
doi:10.1530/REP-16-0052. DOI
9. Anahtar MN et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity.
2015;42(5):965-976. doi:10.1016/j.immuni.2015.04.019. DOI
10. Bourdon M et al. Immunological changes associated with adenomyosis: a systematic review. Hum Reprod Update. 2021;27(1):108-129.
doi:10.1093/humupd/dmaa038. DOI
11. Muraoka A et al. Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial
fibroblasts. Sci Transl Med. 2023;15(700):eadd1531. doi:10.1126/scitranslmed.add1531. DOI
12. Gholiof M, Adamson-De Luca E, Wessels JM. The female reproductive tract microbiotas, inflammation, and gynecological conditions.
Front Reprod Health. 2022;4:963752. doi:10.3389/frph.2022.963752. DOI
13. Yarbrough VL, Winkle S, Herbst-Kralovetz MM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal
immune barrier with physiological and clinical implications. Hum Reprod Update. 2015;21(3):353-377. doi:10.1093/humupd/dmu065. DOI
14. Muytjens CMJ, Yu Y , Diamandis EP . Discovery of antimicrobial peptides in cervical-vaginal fluid from healthy nonpregnant women via
an integrated proteome and peptidome analysis. Proteomics. 2017;17(21):1600461. doi:10.1002/pmic.201600461. DOI
15. Madanchi H et al. Expression of cathelicidin, ERK, MyD88, and TLR-9 in the blood of women in the pre-pregnancy, pregnancy, and their
infant cord blood. Hum Immunol. 2022;83(12):826-831. doi:10.1016/j.humimm.2022.08.014. DOI
The analysis of cervicovaginal microbiota and immune mediators in patients with adenomyosis
1499
16. Agarwal N, Buckley N, Nakra N et al. Activity of genital tract secretions and synthetic antimicrobial peptides against Group B Streptococcus.
Am J Reprod Immunol. 2015;74(6):499-507. doi:10.1111/aji.12427. DOI
17. Doerflinger SY , Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier
properties of the human vaginal epithelia in a species-specific manner. J Infect Dis. 2014;209(12):1989-1999. doi:10.1093/infdis/jiu004.
DOI
18. Chen K, Magri G, Grasset EK, Cerutti A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat Rev Immunol. 2020;20(7):427-
441. doi:10.1038/s41577-019-0261-1. DOI
19. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13(7):657-
664. doi:10.1111/j.1469-0691.2007.01688.x. DOI
20. Haggerty CL, Hillier SL, Bass DC, Ness RB. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis.
2004;39(7):990-995. doi:10.1086/423963. DOI
21. Leonardi M et al. Transvaginal ultrasound can accurately predict the American Society of Reproductive Medicine stage of endometriosis
assigned at laparoscopy. J Minim Invasive Gynecol. 2020;27(7):1581-1587.e1. doi:10.1016/j.jmig.2020.02.014. DOI
22. Larsen B, Monif GRG. Understanding the bacterial flora of the female genital tract. Clin Infect Dis. 2001;32(4):e69-e77. doi:10.1086/318710.
DOI
23. Takimoto K, Yamada H, Shimada S et al. Chronic endometritis and uterine endometrium microbiota in recurrent implantation failure
and recurrent pregnancy loss. Biomedicines. 2023;11(9):2391. doi:10.3390/biomedicines11092391. DOI
24. Azkargorta M et al. In-depth proteomics and natural peptidomics analyses reveal antibacterial peptides in human endometrial fluid. J
Proteomics. 2020;216:103652. doi:10.1016/j.jprot.2020.103652. DOI
25. Cregger M et al. Reproductive microbiomes: using the microbiome as a novel diagnostic tool for endometriosis. Reprod Immunol Open
Access. 2017;2(3):36. doi:10.21767/2476-1974.100036. DOI
26. Dechaud H, Haouzi D, Vincens C et al. New biomarkers of adenomyosis in endometrium. Fertil Steril. 2014;102(3):e49-e50. doi:10.1016/j.
fertnstert.2014.07.172. DOI
27. Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol. 1987;70(1):115-122.
doi:10.1016/0020-7292(88)90292-5. DOI
CONFLICT OF INTEREST
The Authors declare no conflict of interest
CORRESPONDING AUTHOR
Olga Mertsalova
Kharkiv National Medical University
4 Nauky Avenue, 61022, Kharkiv, Ukraine
e-mail:
[email protected]
ORCID AND CONTRIBUTIONSHIP
Mykola Shcherbina: 0000-0003-3605-7204
Liliya Potapova: 0000-0002-2022-5333
Oksana Lipko: 0000-0001-6462-3563
lrina Shcherbina: 0000-0001-7666-8953
Anastasiia Chekhunova: 0000-0002-6509-5747
Olga Mertsalova: 0000-0001-9967-4918
– Work concept and design, – Data collection and analysis, – Responsibility for statistical analysis, – Writing the article, – Critical review, – Final approval of the article
RECEIVED: 07.11.2025
ACCEPTED: 02.03.2026
CREATIVE COMMONS 4.0
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.